Skip to NavigationSkip to content

Lilly's Trulicity reduces major cardiovascular events in "ambitious" trial of type 2 diabetes

Published on 07/11/18 at 11:00am

Eli Lilly has revealed new data on Trulicity (dulaglutide), showing that glucagon-like peptide-1 (GLP-1) receptor agonist achieved its primary endpoint and “significantly reduced” the occurrence of major cardiovascular events (MACE) in patients with type 2 diabetes mellitus.

In the study, MACE included cardiovascular (CV) death, non-fatal myocardial infarction (heart attack) or non-fatal stroke.

The REWIND trial set itself apart from many similar studies by merit of its small population of participants with establish cardiovascular disease – just  31% – which allowed for a more insightful look into Trulicity’s effects on a broader range of those with type 2 diabetes.  

Additionally, the study had the longest median follow-up period of any CV outcomes  trial in the GLP-1 receptor agonist class, at more than five years.

“The REWIND study was ambitious, assessing whether dulaglutide could protect a broad range of people with type 2 diabetes, including a high proportion of patients without established cardiovascular disease, from experiencing a cardiovascular event,” explained Dr Arash Tahbaz, Senior Medical Director at Eli Lilly and Company UK and Northern Europe. “The initial study outcomes are compelling and we look forward to analysing and reporting all of the data.”

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches